A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
Latest Information Update: 18 Sep 2023
Price :
$35 *
At a glance
- Drugs SR T100 (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors G&E Herbal Biotechnology
- 13 Sep 2023 Planned End Date changed from 1 Mar 2021 to 1 Aug 2033.
- 13 Sep 2023 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2033.
- 13 Sep 2023 Planned initiation date changed from 1 Jun 2020 to 1 Sep 2030.